Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Sacituzumab tirumotecan as neoadjuvant therapy for resectable NSCLC
ChiCTR2500111980Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab and sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Primary endpoint: Pathological Complete Response (pCR) Rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
sintilimabsacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500111980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111980.